1. Home
  2. SOC vs GUTS Comparison

SOC vs GUTS Comparison

Compare SOC & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOC
  • GUTS
  • Stock Information
  • Founded
  • SOC 2020
  • GUTS 2010
  • Country
  • SOC United States
  • GUTS United States
  • Employees
  • SOC N/A
  • GUTS N/A
  • Industry
  • SOC
  • GUTS
  • Sector
  • SOC
  • GUTS
  • Exchange
  • SOC Nasdaq
  • GUTS NYSE
  • Market Cap
  • SOC 2.1B
  • GUTS 110.1M
  • IPO Year
  • SOC N/A
  • GUTS 2024
  • Fundamental
  • Price
  • SOC $22.28
  • GUTS $1.79
  • Analyst Decision
  • SOC Buy
  • GUTS Buy
  • Analyst Count
  • SOC 3
  • GUTS 2
  • Target Price
  • SOC $25.00
  • GUTS $18.00
  • AVG Volume (30 Days)
  • SOC 1.4M
  • GUTS 292.2K
  • Earning Date
  • SOC 11-14-2024
  • GUTS 02-02-2025
  • Dividend Yield
  • SOC N/A
  • GUTS N/A
  • EPS Growth
  • SOC N/A
  • GUTS N/A
  • EPS
  • SOC N/A
  • GUTS N/A
  • Revenue
  • SOC N/A
  • GUTS $97,000.00
  • Revenue This Year
  • SOC N/A
  • GUTS N/A
  • Revenue Next Year
  • SOC $606.07
  • GUTS N/A
  • P/E Ratio
  • SOC N/A
  • GUTS N/A
  • Revenue Growth
  • SOC N/A
  • GUTS N/A
  • 52 Week Low
  • SOC $10.11
  • GUTS $1.74
  • 52 Week High
  • SOC $28.67
  • GUTS $14.50
  • Technical
  • Relative Strength Index (RSI)
  • SOC 53.11
  • GUTS 36.46
  • Support Level
  • SOC $19.51
  • GUTS $2.00
  • Resistance Level
  • SOC $24.73
  • GUTS $2.13
  • Average True Range (ATR)
  • SOC 1.60
  • GUTS 0.20
  • MACD
  • SOC 0.12
  • GUTS -0.05
  • Stochastic Oscillator
  • SOC 58.60
  • GUTS 4.76

About SOC Sable Offshore Corp. Common Stock

Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.

About GUTS FRACTYL HEALTH INC

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

Share on Social Networks: